Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | REN | P00797 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3264631 | 0.88 | KCNH2 (0.47) | PDE4BGPR119KCNH2RENCYP3A4 | |
| SCHEMBL3264633 | 0.88 | KCNH2 (0.47) | PDE4BGPR119KCNH2RENCYP3A4 | |
| SCHEMBL556513 | 0.88 | KCNH2 (0.47) | PDE4BGPR119KCNH2RENCYP3A4 | |
| SCHEMBL556676 | 0.87 | GPR119 (0.41) | GPR119KCNH2RENCYP3A4 | |
| SCHEMBL1750732 | 0.86 | PDE4B (0.51) | PDE4BKCNH2RENCYP3A4 | |
| SCHEMBL1751490 | 0.86 | PDE4B (0.51) | PDE4BKCNH2RENCYP3A4 | |
| SCHEMBL2783354 | 0.85 | REN (0.43) | PDE4BGPR119KCNH2RENCYP3A4 | |
| SCHEMBL2783355 | 0.85 | REN (0.43) | PDE4BGPR119KCNH2RENCYP3A4 | |
| SCHEMBL18618571 | 0.85 | GPR119 (0.48) | PDE4BGPR119SCN9A | |
| SCHEMBL556095 | 0.85 | GPR119 (0.40) | GPR119KCNH2RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | PDE4B 357/4885GPR119 487/4885SCN9A 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.